Registration Type

Total participants at ECCO15-ESMO 34 (2009) 14 918
Total participants at Stockholm (2011) 15 931
% increase in participants 6.79%

- Delegates 12 768 (80.15%)
- Invited Speakers 694 (4.36%)
- Exhibitors 1 683 (10.56%)
- Media 363 (2.28%)
- Complimentary, VIP and Guests 423 (2.66%)

Total participants 15 931
Scientific Programme Related Statistics

Total Abstracts Submitted: 2,398

Abstracts submitted at General Deadline: 2,304

Oral Presentations: 181

Poster Presentations: 1,768

Rejected: 355

Abstracts submitted at Late Breaking Deadline: 94

Late Breaking Abstracts Selected: 33

Late Breaking Abstracts Rejected: 61
### Top 10 Countries

- USA (15%)
- United Kingdom (13%)
- Germany (13%)
- France (13%)
- Italy (9%)
- Switzerland (9%)
- China (8%)
- Sweden (7%)
- The Netherlands (7%)
- Japan (6%)

### Continent Overview

- Americas (20%)
- Central & Eastern Europe (21%)
- Asia (19%)
- Europe (17%)
- Middle East (13%)
- Africa (8%)
- Australasia (2%)
Place of Work

<table>
<thead>
<tr>
<th>Place of Work</th>
<th>% of Total Attendance</th>
</tr>
</thead>
<tbody>
<tr>
<td>General hospital</td>
<td>(29.32)</td>
</tr>
<tr>
<td>University hospital</td>
<td>(24.36)</td>
</tr>
<tr>
<td>Industry</td>
<td>(18.63)</td>
</tr>
<tr>
<td>Cancer centre</td>
<td>(11.91)</td>
</tr>
<tr>
<td>University</td>
<td>(5.68)</td>
</tr>
<tr>
<td>Other</td>
<td>(4.27)</td>
</tr>
<tr>
<td>Non-profit organisation</td>
<td>(2.21)</td>
</tr>
<tr>
<td>Cancer research centre</td>
<td>(1.10)</td>
</tr>
<tr>
<td>Private practice</td>
<td>(0.99)</td>
</tr>
<tr>
<td>Publishing centres</td>
<td>(0.71)</td>
</tr>
<tr>
<td>Government</td>
<td>(0.47)</td>
</tr>
<tr>
<td>Contract research organisation</td>
<td>(0.26)</td>
</tr>
<tr>
<td>Investment company</td>
<td>(0.04)</td>
</tr>
<tr>
<td>EU institution</td>
<td>(0.03)</td>
</tr>
</tbody>
</table>

% of total attendance
Specialisation in Main Tumour Type

- All (23.70)
- Breast (16.40)
- Other (11.40)
- Colorectal (9.50)
- Lung (9.10)
- Blood (3.40)
- Prostate (3.30)
- Ovarian (2.70)
- Kidney (2.30)
- Stomach (2.30)
- Liver (2.20)
- Melanoma and skin (2.20)
- Head and neck (2.00)
- Pancreatic (1.90)
- Brain (1.80)
- Soft tissue sarcoma (1.20)
- Bladder (1.10)
- Bone (1.10)
- Cervix (1.00)
- Neuroendocrine (0.70)
- Thyroid (0.70)
- Ocular (0.10)

% of total attendance
Area of Main Interest

Clinical research (27.30)
Drug development (11.90)
Basic science (8.80)
Radiotherapy (6.90)
Systemic therapy (6.00)
Surgery (5.90)
Early drug development (5.00)
Nursing (4.30)
Palliative care (3.90)
Pharmacy (3.50)
Geriatric oncology (3.10)
Pathology (3.10)
Psychosocial oncology (2.90)
Translational research (2.30)
Paediatrics (2.00)
Advocacy (1.80)
Policy (1.10)

% of total attendance
Profession

<table>
<thead>
<tr>
<th>Profession</th>
<th>% of total attendance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical oncologist</td>
<td>40.90</td>
</tr>
<tr>
<td>General physician</td>
<td>8.10</td>
</tr>
<tr>
<td>Nurse</td>
<td>6.50</td>
</tr>
<tr>
<td>Radiotherapist</td>
<td>6.10</td>
</tr>
<tr>
<td>Surgical oncologist</td>
<td>5.40</td>
</tr>
<tr>
<td>Basic scientist</td>
<td>5.20</td>
</tr>
<tr>
<td>Medical affairs</td>
<td>4.90</td>
</tr>
<tr>
<td>Journalist</td>
<td>4.30</td>
</tr>
<tr>
<td>Oncology pharmacist</td>
<td>3.30</td>
</tr>
<tr>
<td>General surgeon</td>
<td>2.30</td>
</tr>
<tr>
<td>Haematologist</td>
<td>2.20</td>
</tr>
<tr>
<td>Student</td>
<td>2.00</td>
</tr>
<tr>
<td>Translational scientist</td>
<td>1.70</td>
</tr>
<tr>
<td>Clinical trial coordinator</td>
<td>1.30</td>
</tr>
<tr>
<td>Paediatric oncologist</td>
<td>1.00</td>
</tr>
<tr>
<td>Gynaecologist</td>
<td>0.70</td>
</tr>
<tr>
<td>Patient advocate</td>
<td>0.70</td>
</tr>
<tr>
<td>Pathologist</td>
<td>0.60</td>
</tr>
<tr>
<td>Radiologist</td>
<td>0.60</td>
</tr>
<tr>
<td>Public relations</td>
<td>0.50</td>
</tr>
<tr>
<td>Urologist</td>
<td>0.50</td>
</tr>
<tr>
<td>Neuro-Oncologist</td>
<td>0.40</td>
</tr>
<tr>
<td>Statistician</td>
<td>0.40</td>
</tr>
<tr>
<td>Public affairs</td>
<td>0.20</td>
</tr>
<tr>
<td>Neurologist</td>
<td>0.10</td>
</tr>
<tr>
<td>Policy maker</td>
<td>0.10</td>
</tr>
<tr>
<td>Regulatory affairs</td>
<td>0.10</td>
</tr>
<tr>
<td>Neuro-Surgeon</td>
<td>0.00</td>
</tr>
</tbody>
</table>
Stats from Website and ECCO App

The ECCO App:

- Over 2,436 downloads of the ECCO App (iOS and Android)
- App use: Users opened 69,000 pages of congress content in the app. That corresponds to 60% of the total page views of the app (the rest is general ECCO information and news).

ECCO Website:

- 34,000 visits to the site during the congress
- 27,700 unique visitors
- Half of all visits came from Swedish IP addresses, hence: US, UK, Germany, Japan, Italy, Switzerland, France, Belgium, Netherlands
- Visitors mainly looked at the online programme and congress practicalities
Social Media Key Figures

**Twitter:**

3,192 tweets during the congress under the hashtag #emcc2011

Top therapy area mentions goes to:

- 382 – GI
- 320 – Breast
- 134 – Prostate
- 122 – Lung

**LinkedIn:**

Having launched the LinkedIn groups from scratch a few weeks prior to the congress the general ECCO group received 250 members.

150 new members in the specific track groups:

- Oncopolicy track group
- Gastrointestinal track group
- Breast cancer track group
- Lung cancer track group
- Drug development track group